Revision history

SUSTAINABILITY OF RARE DISEASE FUND AND AVAILABILITY OF DONOR-AUTHORISED PRINCIPAL FOR CELL, TISSUE AND GENE THERAPY PRODUCTS — 1 version recorded. Nothing here has been overwritten.

1. Version 1 original current
   SUSTAINABILITY OF RARE DISEASE FUND AND AVAILABILITY OF DONOR-AUTHORISED PRINCIPAL FOR CELL, TISSUE AND GENE THERAPY PRODUCTS
   October 07, 2026 04:33